[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586470":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":38,"responsibleParty":57,"collaborators":24,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":24,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Labetalol","EXPERIMENTAL","Participants in this arm will receive oral labetalol to manage postpartum hypertension. The starting dose will be 200 mg twice or three times daily (BID or TID), with adjustments up to 2400 mg\u002Fday (800 mg TID) as needed.",[13],"Drug: Labetalol",{"label":15,"type":10,"description":16,"interventionNames":17},"Nifedipine","Participants in this arm will receive oral extended-release nifedipine to manage postpartum hypertension. The starting dose will be 30 mg once daily, with adjustments up to 120 mg\u002Fday as needed",[18],"Drug: Nifedipine",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Labetalol is a beta-blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral labetalol will be initiated at 200mg twice or three times daily and adjusted up to 2400 mg\u002Fday as needed for blood pressure control.",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"Nifedipine is a calcium channel blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral extended-release nifedipine will be initiated at 30mg once daily and adjusted up to 120mg\u002Fday as needed for blood pressure control.",[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Tina A Nguyen, MD","CONTACT","310-794-7274","tinaanguyen@mednet.ucla.edu",{"name":35,"role":31,"phone":36,"phoneExt":24,"email":37},"Sonia S Raghuram, MS","408-896-8704","sraghuram@mednet.ucla.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"UCLA Ronald Reagan","RECRUITING","Los Angeles","California","90095","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-118.24368,34.05223,{"lat":51,"lon":50},[54],{"name":30,"role":31,"phone":55,"phoneExt":24,"email":56},"9176260405","TinaANguyen@mednet.ucla.edu",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Tina A. Nguyen, MD","Associate Clinical Professor","100586470","phase-4-peace-trial-postpartum-evaluation-of-antihypertensive-cessation-and-efficacy-100586470",false,"NCT06915792","PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy","Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension","PEACE","Inclusion criteria:\n\nAge ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \\> 150 and\u002For DBP \\> 100 OR 2 or more SBP \\> 140 and\u002For DBP \\> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication\n\nExclusion criteria:\n\nTreated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English","FEMALE","18 Years","64 Years",{"count":73,"type":74},110,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.",[80],"Postpartum Hypertension (PPHT)",[82],"postpartum hypertension, blood pressure control, labetalol, nifedipine, antihypertensive therapy, pregnancy hypertension, maternal health, randomized controlled","2026-06-03",{"date":85,"type":86},"2026-06-05","ACTUAL",{"date":88,"type":86},"2025-06-01",{"date":90,"type":74},"2027-10-31",{"name":5,"class":6},1]